Flucloxacillin, still the empirical choice for putative Staphylococcus aureus infections in intensive care units in the Netherlands

Journal of Antimicrobial Chemotherapy

Volumn 64, Issue 5, 2009, Pages

  Rijnders, M I A ^a   Deurenberg, R H ^a   Boumans, M L L ^a   Hoogkamp Korstanje, J A A ^a   Beisser, P S ^a   Stobberingh, E E ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Antibiotic resistance; Critical care; Empirical therapy; ICUs; S. Aureus

Indexed keywords

BACTERIAL PROTEIN; CEFACLOR; CEFUROXIME; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; DOXYCYCLINE; FEMA PROTEIN; FLUCLOXACILLIN; GENTAMICIN; IMIPENEM; LINEZOLID; MEROPENEM; MOXIFLOXACIN; PENICILLIN BINDING PROTEIN 2A; PENICILLIN G; RIFAMPICIN; TEICOPLANIN; UNCLASSIFIED DRUG; VANCOMYCIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CONTROLLED STUDY; DRUG CHOICE; HUMAN; INTENSIVE CARE; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NETHERLANDS; NONHUMAN; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; TREND STUDY; CLINICAL TRIAL; DRUG EFFECT; INTENSIVE CARE UNIT; ISOLATION AND PURIFICATION; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MULTICENTER STUDY;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; FLOXACILLIN; HUMANS; INTENSIVE CARE UNITS; MICROBIAL SENSITIVITY TESTS; NETHERLANDS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 73949135127     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp337     Document Type: Article

References (25)

1. Streit JM, Jones RN, Sader HS et al. Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001). Int J Antimicrob Agents 2004; 24: 111-8.
2. Ibelings MM, Bruining HA. Methicillin-resistant Staphylococcus aureus: acquisition and risk of death in patients in the intensive care unit. Eur J Surg 1998; 164: 411-8.
3. Ito T, Okuma K, Ma XX et al. Insights on antibiotic resistance of Staphylococcus aureus from its whole genome: genomic island SCC. Drug Resist Updat 2003; 6: 41-52.
4. Aarts MA, Brun-Buisson C, Cook DJ et al. Antibiotic management of suspected nosocomial ICU-acquired infection: does prolonged empiric therapy improve outcome? Intensive Care Med 2007; 33: 1369-78.
5. Harbarth S, Garbino J, Pugin J et al. Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. Am J Med 2003; 115: 529-35.
6. SWAB. Nethmap, Consumption of Antimicrobial Agents and Antimicrobial Resistance among Medically Important Bacteria in the Netherlands. Bilthoven: SWAB, 2008.
7. Hoogkamp-Korstanje JA, Roelofs-Willemse J. Antimicrobial resistance in Gram-negative bacteria from intensive care units and urology services. A nationwide study in the Netherlands 1995-2000. Int J Antimicrob Agents 2003; 21: 547-56.
8. Clinical Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twelfth Informational Supplement M100-S12. CLSI, Wayne, PA, USA, 2002.
9. Donker GA, Deurenberg RH, Driessen C et al. The population structure of Staphylococcus aureus among general practice patients from The Netherlands. Clin Microbiol Infect 2009; 15: 137-43.
10. Gastmeier P, Sohr D, Geffers C et al. Risk factors for death due to nosocomial infection in intensive care unit patients: findings from the Krankenhaus Infektions Surveillance System. Infect Control Hosp Epidemiol 2007; 28: 466-72.
11. Vincent JL. Microbial resistance: lessons from the EPIC study. European Prevalence of Infection. Intensive Care Med 2000; 26 Suppl 1: S3-8.
12. Kollef MH, Fraser VJ. Antibiotic resistance in the intensive care unit. Ann Intern Med 2001; 134: 298-314.
13. Papadomichelakis E, Kontopidou F, Antoniadou A et al. Screening for resistant Gram-negative microorganisms to guide empiric therapy of subsequent infection. Intensive Care Med 2008; 34: 2169-75.
14. Blot S, Depuydt P, Vogelaers D. Maximizing rates of empiric appropriate antibiotic therapy with minimized use of broad-spectrum agents: are surveillance cultures the key? Intensive Care Med 2008; 34: 2130-3.
15. Hanberger H, Arman D, Gill H et al. Surveillance of microbial resistance in European Intensive Care Units: a first report from the Care-ICU programme for improved infection control. Intensive Care Med 2008; 35: 91-100.
16. Zhanel GG, DeCorby M, Laing N et al. Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. Antimicrob Agents Chemother 2008; 52: 1430-7.
17. Fridkin SK. Increasing prevalence of antimicrobial resistance in intensive care units. Crit Care Med 2001; 29: N64-8.
18. Bergmans DC, Bonten MJ, Gaillard CA et al. Indications for antibiotic use in ICU patients: a one-year prospective surveillance. J Antimicrob Chemother 1997; 39: 527-35.
19. Hanberger H, Burman LG, Cars O et al. Low antibiotic resistance rates in Staphylococcus aureus, Escherichia coli and Klebsiella spp but not in Enterobacter spp and Pseudomonas aeruginosa: a prospective observational study in 14 Swedish ICUs over a 5-year period. Acta Anaesthesiol Scand 2007; 51: 937-41.
20. Wertheim HF, Vos MC, Boelens HA et al. Low prevalence of methicillin-resistant Staphylococcus aureus (MRSA) at hospital admission in the Netherlands: the value of search and destroy and restrictive antibiotic use. J Hosp Infect 2004; 56: 321-5.
21. EARSS. EARSS Annual Reports. http://www.rivm.nl/earss/ (26 June 2009, date last accessed).
22. Tacconelli E, De Angelis G, Cataldo MA et al. Does antibiotic exposure increase the risk of methicillin-resistant Staphylococcus aureus (MRSA) isolation? A systematic review and meta-analysis. J Antimicrob Chemother 2008; 61: 26-38.
23. Biedenbach DJ, Barrett MS, Croco MA et al. BAY 12-8039, a novel fluoroquinolone. Activity against important respiratory tract pathogens. Diagn Microbiol Infect Dis 1998; 32: 45-50.
24. Sierra JM, Cabeza JG, Ruiz Chaler M et al. The selection of resistance to and the mutagenicity of different fluoroquinolones in Staphylococcus aureus and Streptococcus pneumoniae. Clin Microbiol Infect 2005; 11: 750-8.
25. Noguchi N, Okihara T, Namiki Y et al. Susceptibility and resistance genes to fluoroquinolones in methicillin-resistant Staphylococcus aureus isolated in 2002. Int J Antimicrob Agents 2005; 25: 374-9.